POCUMINT · Proof Of Concept Use of MTH1 Inhibitors as New Treatments for cancer

In our ERC grant GEnetic NEtworks as a tool for anti-CAncer Drug Development we used phenotypic screening and genetic networks to identify the DNA repair protein MTH1 as a critical component for cancer cell survival and we developed selective sub nM inhibitors to MTH1, which specifically kill cancer cells and tumours, whilst being less toxic to primary cells. Our approach provides a novel concept for treating cancer. Here, we want to explore the commercial potential of the MTH1 inhibitors identified in the ERC grant.""